PURCHASE, NY, June 4, 2007 Nutrition 21, Inc. (NASDAQ: NXXI) today announced new published results from a 447 subject, randomized, double-blind, placebo-controlled clinical study that showed Diachrome, a patented combination of chromium picolinate and biotin, significantly improved glycemic control in patients with poorly controlled blood sugar levels who were being treated with oral anti-diabetic medication (OADs). Patients in the treatment group showed significant improvements in glycemic control (A1C) compared with placebo (an absolute decrease of 0.54%). The greatest improvement was seen in those patients with the poorest glycemic control (baseline A1C levels equal to or greater than 10%). These patients saw an additional absolute A1C decrease of 1.76% despite the fact that they were taking one or more OAD medications.
The American Diabetes Associations (ADA) recommended goal for type 2 diabetes patients is an A1C level below 7.0%. Lowering A1C by just 1%, especially in patients with poor blood sugar control, can delay or prevent serious complications, reduce diabetes-related deaths and reduce healthcare costs.
Uncontrolled, obese and overweight type 2 diabetes patients present an ongoing clinical challenge to health professionals. Prescribing another anti-diabetic medication can increase the risk of unwanted side effects, including weight gain or hypoglycemic events, and could place an added financial burden on the patient, said Cesar Albarracin, MD, lead investigator and a leader in the field of nutritional management of type 2 diabetes. This study shows that adding Diachrome to anti-diabetic medications can help patients reach their blood sugar goal simply, effectively and safely.
About the study
The randomized, double-blind, placebo-controlled, 90-day study, published online in Diabetes/Metabolism Research and Reviews (h
'"/>
Contact: Chad Hyett
chad.hyett@fleishman.com
212-453-2493
Nutrition 21
4-Jun-2007